nodes	percent_of_prediction	percent_of_DWPC	metapath
Rimonabant—CYP2D6—Vinorelbine—ovarian cancer	0.122	0.213	CbGbCtD
Rimonabant—CYP3A4—Topotecan—ovarian cancer	0.11	0.192	CbGbCtD
Rimonabant—CYP2C9—Paclitaxel—ovarian cancer	0.0934	0.164	CbGbCtD
Rimonabant—CYP3A4—Vinorelbine—ovarian cancer	0.0773	0.135	CbGbCtD
Rimonabant—CYP3A4—Paclitaxel—ovarian cancer	0.0543	0.0951	CbGbCtD
Rimonabant—CYP2D6—Doxorubicin—ovarian cancer	0.046	0.0806	CbGbCtD
Rimonabant—CYP3A4—Docetaxel—ovarian cancer	0.0393	0.0688	CbGbCtD
Rimonabant—CYP3A4—Doxorubicin—ovarian cancer	0.0293	0.0513	CbGbCtD
Rimonabant—Mediastinal disorder—Melphalan—ovarian cancer	0.0026	0.00609	CcSEcCtD
Rimonabant—Menopausal symptoms—Paclitaxel—ovarian cancer	0.00259	0.00608	CcSEcCtD
Rimonabant—Malnutrition—Topotecan—ovarian cancer	0.00256	0.006	CcSEcCtD
Rimonabant—Hypoglycaemia—Paclitaxel—ovarian cancer	0.00251	0.00588	CcSEcCtD
Rimonabant—Hypoaesthesia—Vinorelbine—ovarian cancer	0.00251	0.00587	CcSEcCtD
Rimonabant—Lethargy—Paclitaxel—ovarian cancer	0.0025	0.00585	CcSEcCtD
Rimonabant—Convulsion—Chlorambucil—ovarian cancer	0.00249	0.00584	CcSEcCtD
Rimonabant—Connective tissue disorder—Vinorelbine—ovarian cancer	0.00247	0.0058	CcSEcCtD
Rimonabant—Muscle spasms—Topotecan—ovarian cancer	0.00246	0.00577	CcSEcCtD
Rimonabant—Infection—Chlorambucil—ovarian cancer	0.00233	0.00547	CcSEcCtD
Rimonabant—Mood swings—Paclitaxel—ovarian cancer	0.00232	0.00544	CcSEcCtD
Rimonabant—Angiopathy—Vinorelbine—ovarian cancer	0.00228	0.00535	CcSEcCtD
Rimonabant—Mediastinal disorder—Vinorelbine—ovarian cancer	0.00227	0.00532	CcSEcCtD
Rimonabant—Anorexia—Chlorambucil—ovarian cancer	0.00224	0.00525	CcSEcCtD
Rimonabant—Hot flush—Docetaxel—ovarian cancer	0.00222	0.0052	CcSEcCtD
Rimonabant—Cramp muscle—Paclitaxel—ovarian cancer	0.0022	0.00517	CcSEcCtD
Rimonabant—Menopausal symptoms—Docetaxel—ovarian cancer	0.0022	0.00515	CcSEcCtD
Rimonabant—Malnutrition—Vinorelbine—ovarian cancer	0.00219	0.00514	CcSEcCtD
Rimonabant—Convulsion—Melphalan—ovarian cancer	0.00217	0.00509	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Topotecan—ovarian cancer	0.00217	0.00508	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Melphalan—ovarian cancer	0.00212	0.00497	CcSEcCtD
Rimonabant—Lethargy—Docetaxel—ovarian cancer	0.00212	0.00496	CcSEcCtD
Rimonabant—Influenza—Paclitaxel—ovarian cancer	0.00212	0.00496	CcSEcCtD
Rimonabant—Infection—Topotecan—ovarian cancer	0.00208	0.00487	CcSEcCtD
Rimonabant—Nervous system disorder—Topotecan—ovarian cancer	0.00205	0.00481	CcSEcCtD
Rimonabant—Decreased appetite—Chlorambucil—ovarian cancer	0.00204	0.00479	CcSEcCtD
Rimonabant—Infection—Melphalan—ovarian cancer	0.00203	0.00477	CcSEcCtD
Rimonabant—Skin disorder—Topotecan—ovarian cancer	0.00203	0.00476	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.00203	0.00475	CcSEcCtD
Rimonabant—Fatigue—Chlorambucil—ovarian cancer	0.00202	0.00475	CcSEcCtD
Rimonabant—Hyperhidrosis—Topotecan—ovarian cancer	0.00202	0.00474	CcSEcCtD
Rimonabant—Anorexia—Topotecan—ovarian cancer	0.00199	0.00467	CcSEcCtD
Rimonabant—Skin disorder—Melphalan—ovarian cancer	0.00199	0.00466	CcSEcCtD
Rimonabant—Upper respiratory tract infection—Paclitaxel—ovarian cancer	0.00197	0.00461	CcSEcCtD
Rimonabant—Anorexia—Melphalan—ovarian cancer	0.00195	0.00457	CcSEcCtD
Rimonabant—Hiccups—Epirubicin—ovarian cancer	0.00193	0.00452	CcSEcCtD
Rimonabant—Gastrointestinal pain—Chlorambucil—ovarian cancer	0.00192	0.0045	CcSEcCtD
Rimonabant—Infestation NOS—Paclitaxel—ovarian cancer	0.00189	0.00442	CcSEcCtD
Rimonabant—Infestation—Paclitaxel—ovarian cancer	0.00189	0.00442	CcSEcCtD
Rimonabant—Depression—Paclitaxel—ovarian cancer	0.00188	0.00441	CcSEcCtD
Rimonabant—Paraesthesia—Topotecan—ovarian cancer	0.00188	0.0044	CcSEcCtD
Rimonabant—Cramp muscle—Docetaxel—ovarian cancer	0.00187	0.00438	CcSEcCtD
Rimonabant—Abdominal pain—Chlorambucil—ovarian cancer	0.00186	0.00435	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.00185	0.00434	CcSEcCtD
Rimonabant—Paraesthesia—Melphalan—ovarian cancer	0.00184	0.00431	CcSEcCtD
Rimonabant—Decreased appetite—Topotecan—ovarian cancer	0.00182	0.00426	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Topotecan—ovarian cancer	0.00181	0.00423	CcSEcCtD
Rimonabant—Fatigue—Topotecan—ovarian cancer	0.0018	0.00423	CcSEcCtD
Rimonabant—Hiccups—Doxorubicin—ovarian cancer	0.00178	0.00418	CcSEcCtD
Rimonabant—Decreased appetite—Melphalan—ovarian cancer	0.00178	0.00417	CcSEcCtD
Rimonabant—Infection—Vinorelbine—ovarian cancer	0.00178	0.00416	CcSEcCtD
Rimonabant—Sinusitis—Paclitaxel—ovarian cancer	0.00177	0.00415	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Melphalan—ovarian cancer	0.00177	0.00414	CcSEcCtD
Rimonabant—Fatigue—Melphalan—ovarian cancer	0.00177	0.00414	CcSEcCtD
Rimonabant—Nervous system disorder—Vinorelbine—ovarian cancer	0.00175	0.00411	CcSEcCtD
Rimonabant—Skin disorder—Vinorelbine—ovarian cancer	0.00174	0.00407	CcSEcCtD
Rimonabant—Gastrointestinal pain—Topotecan—ovarian cancer	0.00171	0.00401	CcSEcCtD
Rimonabant—Anorexia—Vinorelbine—ovarian cancer	0.0017	0.004	CcSEcCtD
Rimonabant—Asthenia—Chlorambucil—ovarian cancer	0.00169	0.00395	CcSEcCtD
Rimonabant—Hypoaesthesia—Paclitaxel—ovarian cancer	0.00168	0.00395	CcSEcCtD
Rimonabant—Connective tissue disorder—Paclitaxel—ovarian cancer	0.00166	0.0039	CcSEcCtD
Rimonabant—Pruritus—Chlorambucil—ovarian cancer	0.00166	0.00389	CcSEcCtD
Rimonabant—Abdominal pain—Topotecan—ovarian cancer	0.00165	0.00387	CcSEcCtD
Rimonabant—Diarrhoea—Chlorambucil—ovarian cancer	0.00161	0.00377	CcSEcCtD
Rimonabant—Paraesthesia—Vinorelbine—ovarian cancer	0.00161	0.00376	CcSEcCtD
Rimonabant—Infestation NOS—Docetaxel—ovarian cancer	0.0016	0.00375	CcSEcCtD
Rimonabant—Infestation—Docetaxel—ovarian cancer	0.0016	0.00375	CcSEcCtD
Rimonabant—Decreased appetite—Vinorelbine—ovarian cancer	0.00155	0.00364	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.00154	0.00362	CcSEcCtD
Rimonabant—Fatigue—Vinorelbine—ovarian cancer	0.00154	0.00361	CcSEcCtD
Rimonabant—Angiopathy—Paclitaxel—ovarian cancer	0.00154	0.0036	CcSEcCtD
Rimonabant—Mediastinal disorder—Paclitaxel—ovarian cancer	0.00153	0.00358	CcSEcCtD
Rimonabant—Asthenia—Topotecan—ovarian cancer	0.0015	0.00352	CcSEcCtD
Rimonabant—Hot flush—Epirubicin—ovarian cancer	0.0015	0.00351	CcSEcCtD
Rimonabant—Vomiting—Chlorambucil—ovarian cancer	0.00149	0.0035	CcSEcCtD
Rimonabant—Mental disorder—Paclitaxel—ovarian cancer	0.00148	0.00348	CcSEcCtD
Rimonabant—Menopausal symptoms—Epirubicin—ovarian cancer	0.00148	0.00348	CcSEcCtD
Rimonabant—Pruritus—Topotecan—ovarian cancer	0.00148	0.00347	CcSEcCtD
Rimonabant—Malnutrition—Paclitaxel—ovarian cancer	0.00147	0.00346	CcSEcCtD
Rimonabant—Asthenia—Melphalan—ovarian cancer	0.00147	0.00344	CcSEcCtD
Rimonabant—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.00146	0.00343	CcSEcCtD
Rimonabant—Pruritus—Melphalan—ovarian cancer	0.00145	0.0034	CcSEcCtD
Rimonabant—Tension—Paclitaxel—ovarian cancer	0.00145	0.00339	CcSEcCtD
Rimonabant—Hypoglycaemia—Epirubicin—ovarian cancer	0.00143	0.00336	CcSEcCtD
Rimonabant—Nervousness—Paclitaxel—ovarian cancer	0.00143	0.00336	CcSEcCtD
Rimonabant—Diarrhoea—Topotecan—ovarian cancer	0.00143	0.00335	CcSEcCtD
Rimonabant—Hypoaesthesia—Docetaxel—ovarian cancer	0.00143	0.00335	CcSEcCtD
Rimonabant—Lethargy—Epirubicin—ovarian cancer	0.00143	0.00335	CcSEcCtD
Rimonabant—Muscle spasms—Paclitaxel—ovarian cancer	0.00142	0.00332	CcSEcCtD
Rimonabant—Abdominal pain—Vinorelbine—ovarian cancer	0.00141	0.00331	CcSEcCtD
Rimonabant—Connective tissue disorder—Docetaxel—ovarian cancer	0.00141	0.00331	CcSEcCtD
Rimonabant—Diarrhoea—Melphalan—ovarian cancer	0.0014	0.00328	CcSEcCtD
Rimonabant—Nausea—Chlorambucil—ovarian cancer	0.0014	0.00327	CcSEcCtD
Rimonabant—Hot flush—Doxorubicin—ovarian cancer	0.00138	0.00324	CcSEcCtD
Rimonabant—Dizziness—Topotecan—ovarian cancer	0.00138	0.00324	CcSEcCtD
Rimonabant—Tremor—Paclitaxel—ovarian cancer	0.00138	0.00324	CcSEcCtD
Rimonabant—Menopausal symptoms—Doxorubicin—ovarian cancer	0.00137	0.00322	CcSEcCtD
Rimonabant—Vomiting—Topotecan—ovarian cancer	0.00133	0.00312	CcSEcCtD
Rimonabant—Hypoglycaemia—Doxorubicin—ovarian cancer	0.00133	0.00311	CcSEcCtD
Rimonabant—Mood swings—Epirubicin—ovarian cancer	0.00133	0.00311	CcSEcCtD
Rimonabant—Lethargy—Doxorubicin—ovarian cancer	0.00132	0.0031	CcSEcCtD
Rimonabant—Rash—Topotecan—ovarian cancer	0.00132	0.00309	CcSEcCtD
Rimonabant—Dermatitis—Topotecan—ovarian cancer	0.00132	0.00309	CcSEcCtD
Rimonabant—Headache—Topotecan—ovarian cancer	0.00131	0.00307	CcSEcCtD
Rimonabant—Angiopathy—Docetaxel—ovarian cancer	0.0013	0.00305	CcSEcCtD
Rimonabant—Vomiting—Melphalan—ovarian cancer	0.0013	0.00305	CcSEcCtD
Rimonabant—Mediastinal disorder—Docetaxel—ovarian cancer	0.00129	0.00303	CcSEcCtD
Rimonabant—Rash—Melphalan—ovarian cancer	0.00129	0.00303	CcSEcCtD
Rimonabant—Dermatitis—Melphalan—ovarian cancer	0.00129	0.00302	CcSEcCtD
Rimonabant—Asthenia—Vinorelbine—ovarian cancer	0.00128	0.00301	CcSEcCtD
Rimonabant—Convulsion—Paclitaxel—ovarian cancer	0.00128	0.00299	CcSEcCtD
Rimonabant—Pruritus—Vinorelbine—ovarian cancer	0.00127	0.00297	CcSEcCtD
Rimonabant—Mental disorder—Docetaxel—ovarian cancer	0.00126	0.00295	CcSEcCtD
Rimonabant—Anxiety—Paclitaxel—ovarian cancer	0.00125	0.00293	CcSEcCtD
Rimonabant—Malnutrition—Docetaxel—ovarian cancer	0.00125	0.00293	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.00125	0.00292	CcSEcCtD
Rimonabant—Nausea—Topotecan—ovarian cancer	0.00124	0.00291	CcSEcCtD
Rimonabant—Dry mouth—Paclitaxel—ovarian cancer	0.00123	0.00288	CcSEcCtD
Rimonabant—Mood swings—Doxorubicin—ovarian cancer	0.00123	0.00288	CcSEcCtD
Rimonabant—Diarrhoea—Vinorelbine—ovarian cancer	0.00122	0.00287	CcSEcCtD
Rimonabant—Nausea—Melphalan—ovarian cancer	0.00122	0.00285	CcSEcCtD
Rimonabant—Influenza—Epirubicin—ovarian cancer	0.00121	0.00283	CcSEcCtD
Rimonabant—Muscle spasms—Docetaxel—ovarian cancer	0.0012	0.00282	CcSEcCtD
Rimonabant—Infection—Paclitaxel—ovarian cancer	0.0012	0.0028	CcSEcCtD
Rimonabant—Dizziness—Vinorelbine—ovarian cancer	0.00118	0.00277	CcSEcCtD
Rimonabant—Nervous system disorder—Paclitaxel—ovarian cancer	0.00118	0.00277	CcSEcCtD
Rimonabant—Skin disorder—Paclitaxel—ovarian cancer	0.00117	0.00274	CcSEcCtD
Rimonabant—Hyperhidrosis—Paclitaxel—ovarian cancer	0.00116	0.00273	CcSEcCtD
Rimonabant—Anorexia—Paclitaxel—ovarian cancer	0.00115	0.00269	CcSEcCtD
Rimonabant—Vomiting—Vinorelbine—ovarian cancer	0.00114	0.00267	CcSEcCtD
Rimonabant—Rash—Vinorelbine—ovarian cancer	0.00113	0.00264	CcSEcCtD
Rimonabant—Dermatitis—Vinorelbine—ovarian cancer	0.00113	0.00264	CcSEcCtD
Rimonabant—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.00112	0.00263	CcSEcCtD
Rimonabant—Headache—Vinorelbine—ovarian cancer	0.00112	0.00263	CcSEcCtD
Rimonabant—Influenza—Doxorubicin—ovarian cancer	0.00112	0.00262	CcSEcCtD
Rimonabant—Insomnia—Paclitaxel—ovarian cancer	0.00109	0.00255	CcSEcCtD
Rimonabant—Convulsion—Docetaxel—ovarian cancer	0.00108	0.00254	CcSEcCtD
Rimonabant—Paraesthesia—Paclitaxel—ovarian cancer	0.00108	0.00253	CcSEcCtD
Rimonabant—Infestation NOS—Epirubicin—ovarian cancer	0.00108	0.00253	CcSEcCtD
Rimonabant—Infestation—Epirubicin—ovarian cancer	0.00108	0.00253	CcSEcCtD
Rimonabant—Nausea—Vinorelbine—ovarian cancer	0.00106	0.00249	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.00106	0.00248	CcSEcCtD
Rimonabant—Decreased appetite—Paclitaxel—ovarian cancer	0.00105	0.00245	CcSEcCtD
Rimonabant—Dry mouth—Docetaxel—ovarian cancer	0.00104	0.00244	CcSEcCtD
Rimonabant—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.00104	0.00244	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.00104	0.00243	CcSEcCtD
Rimonabant—Fatigue—Paclitaxel—ovarian cancer	0.00104	0.00243	CcSEcCtD
Rimonabant—Infection—Docetaxel—ovarian cancer	0.00101	0.00237	CcSEcCtD
Rimonabant—Sinusitis—Epirubicin—ovarian cancer	0.00101	0.00237	CcSEcCtD
Rimonabant—Nervous system disorder—Docetaxel—ovarian cancer	0.001	0.00234	CcSEcCtD
Rimonabant—Infestation NOS—Doxorubicin—ovarian cancer	0.000998	0.00234	CcSEcCtD
Rimonabant—Infestation—Doxorubicin—ovarian cancer	0.000998	0.00234	CcSEcCtD
Rimonabant—Skin disorder—Docetaxel—ovarian cancer	0.000991	0.00232	CcSEcCtD
Rimonabant—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000984	0.00231	CcSEcCtD
Rimonabant—Anorexia—Docetaxel—ovarian cancer	0.000972	0.00228	CcSEcCtD
Rimonabant—Hypoaesthesia—Epirubicin—ovarian cancer	0.000963	0.00226	CcSEcCtD
Rimonabant—Connective tissue disorder—Epirubicin—ovarian cancer	0.000951	0.00223	CcSEcCtD
Rimonabant—Abdominal pain—Paclitaxel—ovarian cancer	0.000951	0.00223	CcSEcCtD
Rimonabant—Sinusitis—Doxorubicin—ovarian cancer	0.000936	0.00219	CcSEcCtD
Rimonabant—Insomnia—Docetaxel—ovarian cancer	0.000922	0.00216	CcSEcCtD
Rimonabant—Paraesthesia—Docetaxel—ovarian cancer	0.000916	0.00215	CcSEcCtD
Rimonabant—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000891	0.00209	CcSEcCtD
Rimonabant—Decreased appetite—Docetaxel—ovarian cancer	0.000886	0.00208	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.00088	0.00206	CcSEcCtD
Rimonabant—Connective tissue disorder—Doxorubicin—ovarian cancer	0.00088	0.00206	CcSEcCtD
Rimonabant—Fatigue—Docetaxel—ovarian cancer	0.000879	0.00206	CcSEcCtD
Rimonabant—Angiopathy—Epirubicin—ovarian cancer	0.000878	0.00206	CcSEcCtD
Rimonabant—Mediastinal disorder—Epirubicin—ovarian cancer	0.000873	0.00205	CcSEcCtD
Rimonabant—Asthenia—Paclitaxel—ovarian cancer	0.000863	0.00202	CcSEcCtD
Rimonabant—Pruritus—Paclitaxel—ovarian cancer	0.000851	0.002	CcSEcCtD
Rimonabant—Mental disorder—Epirubicin—ovarian cancer	0.000848	0.00199	CcSEcCtD
Rimonabant—Malnutrition—Epirubicin—ovarian cancer	0.000843	0.00198	CcSEcCtD
Rimonabant—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000834	0.00195	CcSEcCtD
Rimonabant—Tension—Epirubicin—ovarian cancer	0.000827	0.00194	CcSEcCtD
Rimonabant—Diarrhoea—Paclitaxel—ovarian cancer	0.000823	0.00193	CcSEcCtD
Rimonabant—Nervousness—Epirubicin—ovarian cancer	0.000819	0.00192	CcSEcCtD
Rimonabant—Angiopathy—Doxorubicin—ovarian cancer	0.000813	0.0019	CcSEcCtD
Rimonabant—Muscle spasms—Epirubicin—ovarian cancer	0.00081	0.0019	CcSEcCtD
Rimonabant—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000807	0.00189	CcSEcCtD
Rimonabant—Abdominal pain—Docetaxel—ovarian cancer	0.000806	0.00189	CcSEcCtD
Rimonabant—Dizziness—Paclitaxel—ovarian cancer	0.000796	0.00186	CcSEcCtD
Rimonabant—Mental disorder—Doxorubicin—ovarian cancer	0.000785	0.00184	CcSEcCtD
Rimonabant—Malnutrition—Doxorubicin—ovarian cancer	0.00078	0.00183	CcSEcCtD
Rimonabant—Tension—Doxorubicin—ovarian cancer	0.000765	0.00179	CcSEcCtD
Rimonabant—Vomiting—Paclitaxel—ovarian cancer	0.000765	0.00179	CcSEcCtD
Rimonabant—Rash—Paclitaxel—ovarian cancer	0.000759	0.00178	CcSEcCtD
Rimonabant—Dermatitis—Paclitaxel—ovarian cancer	0.000758	0.00178	CcSEcCtD
Rimonabant—Nervousness—Doxorubicin—ovarian cancer	0.000757	0.00178	CcSEcCtD
Rimonabant—Headache—Paclitaxel—ovarian cancer	0.000754	0.00177	CcSEcCtD
Rimonabant—Muscle spasms—Doxorubicin—ovarian cancer	0.00075	0.00176	CcSEcCtD
Rimonabant—Asthenia—Docetaxel—ovarian cancer	0.000732	0.00171	CcSEcCtD
Rimonabant—Convulsion—Epirubicin—ovarian cancer	0.00073	0.00171	CcSEcCtD
Rimonabant—Pruritus—Docetaxel—ovarian cancer	0.000721	0.00169	CcSEcCtD
Rimonabant—Anxiety—Epirubicin—ovarian cancer	0.000715	0.00168	CcSEcCtD
Rimonabant—Nausea—Paclitaxel—ovarian cancer	0.000715	0.00167	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000713	0.00167	CcSEcCtD
Rimonabant—Dry mouth—Epirubicin—ovarian cancer	0.000702	0.00164	CcSEcCtD
Rimonabant—Diarrhoea—Docetaxel—ovarian cancer	0.000698	0.00164	CcSEcCtD
Rimonabant—Infection—Epirubicin—ovarian cancer	0.000683	0.0016	CcSEcCtD
Rimonabant—Convulsion—Doxorubicin—ovarian cancer	0.000676	0.00158	CcSEcCtD
Rimonabant—Nervous system disorder—Epirubicin—ovarian cancer	0.000675	0.00158	CcSEcCtD
Rimonabant—Dizziness—Docetaxel—ovarian cancer	0.000674	0.00158	CcSEcCtD
Rimonabant—Skin disorder—Epirubicin—ovarian cancer	0.000668	0.00157	CcSEcCtD
Rimonabant—Hyperhidrosis—Epirubicin—ovarian cancer	0.000665	0.00156	CcSEcCtD
Rimonabant—Anxiety—Doxorubicin—ovarian cancer	0.000662	0.00155	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000659	0.00155	CcSEcCtD
Rimonabant—Anorexia—Epirubicin—ovarian cancer	0.000656	0.00154	CcSEcCtD
Rimonabant—Dry mouth—Doxorubicin—ovarian cancer	0.000649	0.00152	CcSEcCtD
Rimonabant—Vomiting—Docetaxel—ovarian cancer	0.000648	0.00152	CcSEcCtD
Rimonabant—Rash—Docetaxel—ovarian cancer	0.000643	0.00151	CcSEcCtD
Rimonabant—Dermatitis—Docetaxel—ovarian cancer	0.000642	0.00151	CcSEcCtD
Rimonabant—Headache—Docetaxel—ovarian cancer	0.000639	0.0015	CcSEcCtD
Rimonabant—Infection—Doxorubicin—ovarian cancer	0.000632	0.00148	CcSEcCtD
Rimonabant—Nervous system disorder—Doxorubicin—ovarian cancer	0.000624	0.00146	CcSEcCtD
Rimonabant—Insomnia—Epirubicin—ovarian cancer	0.000622	0.00146	CcSEcCtD
Rimonabant—Skin disorder—Doxorubicin—ovarian cancer	0.000618	0.00145	CcSEcCtD
Rimonabant—Paraesthesia—Epirubicin—ovarian cancer	0.000618	0.00145	CcSEcCtD
Rimonabant—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000615	0.00144	CcSEcCtD
Rimonabant—Anorexia—Doxorubicin—ovarian cancer	0.000607	0.00142	CcSEcCtD
Rimonabant—Nausea—Docetaxel—ovarian cancer	0.000606	0.00142	CcSEcCtD
Rimonabant—Decreased appetite—Epirubicin—ovarian cancer	0.000598	0.0014	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000594	0.00139	CcSEcCtD
Rimonabant—Fatigue—Epirubicin—ovarian cancer	0.000593	0.00139	CcSEcCtD
Rimonabant—Insomnia—Doxorubicin—ovarian cancer	0.000576	0.00135	CcSEcCtD
Rimonabant—Paraesthesia—Doxorubicin—ovarian cancer	0.000571	0.00134	CcSEcCtD
Rimonabant—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000562	0.00132	CcSEcCtD
Rimonabant—Decreased appetite—Doxorubicin—ovarian cancer	0.000553	0.0013	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000549	0.00129	CcSEcCtD
Rimonabant—Fatigue—Doxorubicin—ovarian cancer	0.000549	0.00129	CcSEcCtD
Rimonabant—Abdominal pain—Epirubicin—ovarian cancer	0.000544	0.00127	CcSEcCtD
Rimonabant—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.00052	0.00122	CcSEcCtD
Rimonabant—Abdominal pain—Doxorubicin—ovarian cancer	0.000503	0.00118	CcSEcCtD
Rimonabant—Asthenia—Epirubicin—ovarian cancer	0.000493	0.00116	CcSEcCtD
Rimonabant—Pruritus—Epirubicin—ovarian cancer	0.000487	0.00114	CcSEcCtD
Rimonabant—Diarrhoea—Epirubicin—ovarian cancer	0.000471	0.0011	CcSEcCtD
Rimonabant—Asthenia—Doxorubicin—ovarian cancer	0.000457	0.00107	CcSEcCtD
Rimonabant—Dizziness—Epirubicin—ovarian cancer	0.000455	0.00107	CcSEcCtD
Rimonabant—Pruritus—Doxorubicin—ovarian cancer	0.00045	0.00106	CcSEcCtD
Rimonabant—Vomiting—Epirubicin—ovarian cancer	0.000437	0.00103	CcSEcCtD
Rimonabant—Diarrhoea—Doxorubicin—ovarian cancer	0.000435	0.00102	CcSEcCtD
Rimonabant—Rash—Epirubicin—ovarian cancer	0.000434	0.00102	CcSEcCtD
Rimonabant—Dermatitis—Epirubicin—ovarian cancer	0.000433	0.00102	CcSEcCtD
Rimonabant—Headache—Epirubicin—ovarian cancer	0.000431	0.00101	CcSEcCtD
Rimonabant—Dizziness—Doxorubicin—ovarian cancer	0.000421	0.000986	CcSEcCtD
Rimonabant—Nausea—Epirubicin—ovarian cancer	0.000409	0.000958	CcSEcCtD
Rimonabant—Vomiting—Doxorubicin—ovarian cancer	0.000405	0.000948	CcSEcCtD
Rimonabant—Rash—Doxorubicin—ovarian cancer	0.000401	0.000941	CcSEcCtD
Rimonabant—Dermatitis—Doxorubicin—ovarian cancer	0.000401	0.00094	CcSEcCtD
Rimonabant—Headache—Doxorubicin—ovarian cancer	0.000399	0.000934	CcSEcCtD
Rimonabant—Nausea—Doxorubicin—ovarian cancer	0.000378	0.000886	CcSEcCtD
Rimonabant—CNR1—BDNF signaling pathway—HRAS—ovarian cancer	1.15e-05	0.00445	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—PPP1CC—ovarian cancer	1.12e-05	0.00432	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—HDAC6—ovarian cancer	1.08e-05	0.00417	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—PPP2R1A—ovarian cancer	1.07e-05	0.00411	CbGpPWpGaD
Rimonabant—CNR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—ovarian cancer	1.05e-05	0.00407	CbGpPWpGaD
Rimonabant—CNR2—GPCR ligand binding—CXCL8—ovarian cancer	1.02e-05	0.00395	CbGpPWpGaD
Rimonabant—CNR1—BDNF signaling pathway—AKT1—ovarian cancer	1.02e-05	0.00393	CbGpPWpGaD
Rimonabant—CYP1A2—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	1.01e-05	0.00391	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—ovarian cancer	9.7e-06	0.00375	CbGpPWpGaD
Rimonabant—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	9.63e-06	0.00372	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—YAP1—ovarian cancer	9.55e-06	0.00369	CbGpPWpGaD
Rimonabant—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	9.51e-06	0.00367	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—XIAP—ovarian cancer	9.36e-06	0.00362	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—SMARCA4—ovarian cancer	9.12e-06	0.00352	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—EREG—ovarian cancer	8.9e-06	0.00344	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—HDAC6—ovarian cancer	8.47e-06	0.00327	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—PPP2R1A—ovarian cancer	8.36e-06	0.00323	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—PGR—ovarian cancer	8.34e-06	0.00322	CbGpPWpGaD
Rimonabant—CNR1—GPCR ligand binding—CXCL8—ovarian cancer	8.03e-06	0.0031	CbGpPWpGaD
Rimonabant—CNR2—GPCR downstream signaling—PIK3CG—ovarian cancer	7.85e-06	0.00303	CbGpPWpGaD
Rimonabant—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	7.81e-06	0.00302	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—PARP1—ovarian cancer	7.76e-06	0.003	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—YAP1—ovarian cancer	7.5e-06	0.0029	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—IL6ST—ovarian cancer	7.42e-06	0.00287	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—XIAP—ovarian cancer	7.35e-06	0.00284	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—SMARCA4—ovarian cancer	7.16e-06	0.00277	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—PIK3CG—ovarian cancer	7.13e-06	0.00275	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—EREG—ovarian cancer	6.99e-06	0.0027	CbGpPWpGaD
Rimonabant—CNR2—GPCR downstream signaling—PIK3CD—ovarian cancer	6.9e-06	0.00267	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—ovarian cancer	6.59e-06	0.00255	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—ovarian cancer	6.59e-06	0.00255	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—PGR—ovarian cancer	6.55e-06	0.00253	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—ovarian cancer	6.45e-06	0.00249	CbGpPWpGaD
Rimonabant—CYP2D6—Biological oxidations—CYP1B1—ovarian cancer	6.35e-06	0.00245	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—PPP2R1A—ovarian cancer	6.29e-06	0.00243	CbGpPWpGaD
Rimonabant—CYP2C9—Biological oxidations—CYP1B1—ovarian cancer	6.29e-06	0.00243	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—PIK3CD—ovarian cancer	6.27e-06	0.00242	CbGpPWpGaD
Rimonabant—CYP2D6—Metapathway biotransformation—CYP1B1—ovarian cancer	6.26e-06	0.00242	CbGpPWpGaD
Rimonabant—CYP2C9—Metapathway biotransformation—CYP1B1—ovarian cancer	6.2e-06	0.0024	CbGpPWpGaD
Rimonabant—CNR1—GPCR downstream signaling—PIK3CG—ovarian cancer	6.16e-06	0.00238	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—PARP1—ovarian cancer	6.09e-06	0.00235	CbGpPWpGaD
Rimonabant—CNR2—GPCR downstream signaling—PIK3CB—ovarian cancer	6.02e-06	0.00232	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—IL6ST—ovarian cancer	5.82e-06	0.00225	CbGpPWpGaD
Rimonabant—CNR2—GPCR downstream signaling—CXCL8—ovarian cancer	5.78e-06	0.00223	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—PIK3CG—ovarian cancer	5.59e-06	0.00216	CbGpPWpGaD
Rimonabant—CNR2—GPCR downstream signaling—IL2—ovarian cancer	5.52e-06	0.00213	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—ovarian cancer	5.48e-06	0.00212	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—PIK3CB—ovarian cancer	5.46e-06	0.00211	CbGpPWpGaD
Rimonabant—CNR1—GPCR downstream signaling—PIK3CD—ovarian cancer	5.42e-06	0.00209	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—ovarian cancer	5.41e-06	0.00209	CbGpPWpGaD
Rimonabant—CYP1A2—Biological oxidations—CYP1B1—ovarian cancer	5.38e-06	0.00208	CbGpPWpGaD
Rimonabant—CYP1A2—Metapathway biotransformation—CYP1B1—ovarian cancer	5.3e-06	0.00205	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—CXCL8—ovarian cancer	5.25e-06	0.00203	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—MYC—ovarian cancer	5.04e-06	0.00195	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—IL2—ovarian cancer	5.02e-06	0.00194	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—TERT—ovarian cancer	5e-06	0.00193	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—PPP2R1A—ovarian cancer	4.94e-06	0.00191	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—ovarian cancer	4.93e-06	0.00191	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—ovarian cancer	4.93e-06	0.00191	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—ovarian cancer	4.93e-06	0.00191	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—PIK3CD—ovarian cancer	4.92e-06	0.0019	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	4.85e-06	0.00187	CbGpPWpGaD
Rimonabant—CNR1—GPCR downstream signaling—PIK3CB—ovarian cancer	4.72e-06	0.00182	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—ovarian cancer	4.66e-06	0.0018	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—CAV1—ovarian cancer	4.62e-06	0.00179	CbGpPWpGaD
Rimonabant—CNR1—GPCR downstream signaling—CXCL8—ovarian cancer	4.54e-06	0.00175	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—ESR1—ovarian cancer	4.45e-06	0.00172	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—IL6ST—ovarian cancer	4.38e-06	0.00169	CbGpPWpGaD
Rimonabant—CNR1—GPCR downstream signaling—IL2—ovarian cancer	4.33e-06	0.00167	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—PIK3CB—ovarian cancer	4.29e-06	0.00166	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—PIK3CG—ovarian cancer	4.21e-06	0.00163	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—APC—ovarian cancer	4.21e-06	0.00163	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—NRAS—ovarian cancer	4.21e-06	0.00163	CbGpPWpGaD
Rimonabant—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	4.15e-06	0.0016	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	4.15e-06	0.0016	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—CXCL8—ovarian cancer	4.12e-06	0.00159	CbGpPWpGaD
Rimonabant—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	4.09e-06	0.00158	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—MAPK3—ovarian cancer	4.03e-06	0.00156	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—ovarian cancer	3.96e-06	0.00153	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—IL2—ovarian cancer	3.94e-06	0.00152	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—TERT—ovarian cancer	3.92e-06	0.00152	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—NME2—ovarian cancer	3.87e-06	0.00149	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—MAPK1—ovarian cancer	3.84e-06	0.00148	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—EGFR—ovarian cancer	3.84e-06	0.00148	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—NME2—ovarian cancer	3.84e-06	0.00148	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—PIK3CD—ovarian cancer	3.7e-06	0.00143	CbGpPWpGaD
Rimonabant—CNR2—GPCR downstream signaling—PIK3CA—ovarian cancer	3.67e-06	0.00142	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—CAV1—ovarian cancer	3.63e-06	0.0014	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—KRAS—ovarian cancer	3.62e-06	0.0014	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—ESR1—ovarian cancer	3.5e-06	0.00135	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—IL6ST—ovarian cancer	3.44e-06	0.00133	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—PIK3CA—ovarian cancer	3.33e-06	0.00129	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—APC—ovarian cancer	3.3e-06	0.00128	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—PIK3CG—ovarian cancer	3.3e-06	0.00128	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—NRAS—ovarian cancer	3.3e-06	0.00128	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—NME2—ovarian cancer	3.28e-06	0.00127	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—ERBB2—ovarian cancer	3.27e-06	0.00126	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	3.25e-06	0.00126	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—MTOR—ovarian cancer	3.23e-06	0.00125	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—PIK3CB—ovarian cancer	3.23e-06	0.00125	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—MAPK3—ovarian cancer	3.16e-06	0.00122	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—CXCL8—ovarian cancer	3.1e-06	0.0012	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—HRAS—ovarian cancer	3.08e-06	0.00119	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—CDKN1B—ovarian cancer	3.03e-06	0.00117	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—MAPK1—ovarian cancer	3.01e-06	0.00116	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—EGFR—ovarian cancer	3.01e-06	0.00116	CbGpPWpGaD
Rimonabant—CNR2—GPCR downstream signaling—AKT1—ovarian cancer	3e-06	0.00116	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—CASP3—ovarian cancer	2.97e-06	0.00115	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—IL2—ovarian cancer	2.96e-06	0.00114	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—IL6—ovarian cancer	2.95e-06	0.00114	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—PIK3CD—ovarian cancer	2.9e-06	0.00112	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—CCND1—ovarian cancer	2.89e-06	0.00112	CbGpPWpGaD
Rimonabant—CNR1—GPCR downstream signaling—PIK3CA—ovarian cancer	2.88e-06	0.00111	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—CTNNB1—ovarian cancer	2.86e-06	0.00111	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—KRAS—ovarian cancer	2.84e-06	0.0011	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—MMP9—ovarian cancer	2.8e-06	0.00108	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—PTEN—ovarian cancer	2.79e-06	0.00108	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	2.78e-06	0.00107	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—AKT1—ovarian cancer	2.72e-06	0.00105	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	2.65e-06	0.00102	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—PIK3CA—ovarian cancer	2.61e-06	0.00101	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—ERBB2—ovarian cancer	2.57e-06	0.000991	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—MTOR—ovarian cancer	2.53e-06	0.000978	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—PIK3CB—ovarian cancer	2.53e-06	0.000978	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—NME2—ovarian cancer	2.53e-06	0.000977	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—VEGFA—ovarian cancer	2.52e-06	0.000973	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—STAT3—ovarian cancer	2.49e-06	0.000963	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—CYTB—ovarian cancer	2.49e-06	0.000963	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—NRAS—ovarian cancer	2.49e-06	0.000961	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—CYTB—ovarian cancer	2.47e-06	0.000955	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—CXCL8—ovarian cancer	2.43e-06	0.00094	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—HRAS—ovarian cancer	2.42e-06	0.000934	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.42e-06	0.000933	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—MAPK3—ovarian cancer	2.38e-06	0.00092	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—CDKN1B—ovarian cancer	2.38e-06	0.000918	CbGpPWpGaD
Rimonabant—CNR1—GPCR downstream signaling—AKT1—ovarian cancer	2.35e-06	0.000908	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—CASP3—ovarian cancer	2.33e-06	0.0009	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—IL2—ovarian cancer	2.33e-06	0.000898	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—MYC—ovarian cancer	2.32e-06	0.000895	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—IL6—ovarian cancer	2.31e-06	0.000894	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—MAPK1—ovarian cancer	2.27e-06	0.000876	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—CCND1—ovarian cancer	2.27e-06	0.000876	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—EGFR—ovarian cancer	2.27e-06	0.000876	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	2.27e-06	0.000876	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—CTNNB1—ovarian cancer	2.24e-06	0.000867	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—MMP9—ovarian cancer	2.2e-06	0.00085	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—PTEN—ovarian cancer	2.19e-06	0.000845	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—PPP1CC—ovarian cancer	2.18e-06	0.000842	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—BRIP1—ovarian cancer	2.18e-06	0.000842	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—PPP1CC—ovarian cancer	2.16e-06	0.000835	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—BRIP1—ovarian cancer	2.16e-06	0.000835	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—KRAS—ovarian cancer	2.14e-06	0.000827	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—AKT1—ovarian cancer	2.13e-06	0.000825	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—CYTB—ovarian cancer	2.11e-06	0.000816	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.06e-06	0.000797	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—VEGFA—ovarian cancer	1.98e-06	0.000764	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—PIK3CA—ovarian cancer	1.97e-06	0.00076	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—STAT3—ovarian cancer	1.96e-06	0.000756	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—NRAS—ovarian cancer	1.95e-06	0.000754	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—TP53—ovarian cancer	1.9e-06	0.000735	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—MAPK3—ovarian cancer	1.87e-06	0.000722	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—PPP1CC—ovarian cancer	1.85e-06	0.000713	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—BRIP1—ovarian cancer	1.85e-06	0.000713	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—HRAS—ovarian cancer	1.82e-06	0.000703	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—MYC—ovarian cancer	1.82e-06	0.000702	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—MAPK1—ovarian cancer	1.78e-06	0.000687	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—EGFR—ovarian cancer	1.78e-06	0.000687	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—IL6—ovarian cancer	1.74e-06	0.000673	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—KRAS—ovarian cancer	1.68e-06	0.000649	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—CYTB—ovarian cancer	1.63e-06	0.00063	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—AKT1—ovarian cancer	1.61e-06	0.000621	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.57e-06	0.000608	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—PIK3CA—ovarian cancer	1.54e-06	0.000596	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—TP53—ovarian cancer	1.49e-06	0.000577	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—YAP1—ovarian cancer	1.46e-06	0.000565	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—YAP1—ovarian cancer	1.45e-06	0.00056	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.43e-06	0.000554	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—HRAS—ovarian cancer	1.43e-06	0.000552	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—PPP1CC—ovarian cancer	1.42e-06	0.00055	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—BRIP1—ovarian cancer	1.42e-06	0.00055	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—IL6—ovarian cancer	1.37e-06	0.000528	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.35e-06	0.00052	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—AKT1—ovarian cancer	1.26e-06	0.000487	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.26e-06	0.000487	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—YAP1—ovarian cancer	1.24e-06	0.000478	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.23e-06	0.000473	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—FASN—ovarian cancer	1.19e-06	0.00046	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—FASN—ovarian cancer	1.18e-06	0.000456	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—SLC5A5—ovarian cancer	1.17e-06	0.000453	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—SLC5A5—ovarian cancer	1.16e-06	0.000449	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—SLC2A1—ovarian cancer	1.13e-06	0.000437	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—SLC2A1—ovarian cancer	1.12e-06	0.000434	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.1e-06	0.000424	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—CYP1B1—ovarian cancer	1.09e-06	0.000419	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.08e-06	0.000416	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—CYP1B1—ovarian cancer	1.08e-06	0.000416	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—FASN—ovarian cancer	1.01e-06	0.00039	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—SLC5A5—ovarian cancer	9.93e-07	0.000384	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	9.62e-07	0.000372	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—SLC2A1—ovarian cancer	9.59e-07	0.00037	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—YAP1—ovarian cancer	9.56e-07	0.000369	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	9.54e-07	0.000369	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	9.49e-07	0.000367	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	9.39e-07	0.000363	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—CYP1B1—ovarian cancer	9.19e-07	0.000355	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—ABCB1—ovarian cancer	8.94e-07	0.000345	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—ABCB1—ovarian cancer	8.86e-07	0.000342	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—TYMS—ovarian cancer	8.78e-07	0.000339	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—TYMS—ovarian cancer	8.7e-07	0.000336	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	8.15e-07	0.000315	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	8.11e-07	0.000313	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—FASN—ovarian cancer	7.79e-07	0.000301	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—SLC5A5—ovarian cancer	7.66e-07	0.000296	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—ABCB1—ovarian cancer	7.57e-07	0.000292	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—TYMS—ovarian cancer	7.43e-07	0.000287	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—SLC2A1—ovarian cancer	7.4e-07	0.000286	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—CYP1B1—ovarian cancer	7.09e-07	0.000274	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—CAV1—ovarian cancer	7.07e-07	0.000273	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—CAV1—ovarian cancer	7.01e-07	0.000271	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	6.7e-07	0.000259	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—PIK3CG—ovarian cancer	6.44e-07	0.000249	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—PIK3CG—ovarian cancer	6.39e-07	0.000247	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	6.29e-07	0.000243	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—CAV1—ovarian cancer	5.99e-07	0.000231	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—ABCB1—ovarian cancer	5.84e-07	0.000226	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—TYMS—ovarian cancer	5.74e-07	0.000222	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	5.72e-07	0.000221	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—PIK3CD—ovarian cancer	5.66e-07	0.000219	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—PIK3CD—ovarian cancer	5.61e-07	0.000217	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—PIK3CG—ovarian cancer	5.46e-07	0.000211	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—PIK3CB—ovarian cancer	4.94e-07	0.000191	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—PIK3CB—ovarian cancer	4.89e-07	0.000189	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—PIK3CD—ovarian cancer	4.8e-07	0.000185	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—CAV1—ovarian cancer	4.62e-07	0.000179	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—PTEN—ovarian cancer	4.27e-07	0.000165	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—PTEN—ovarian cancer	4.23e-07	0.000163	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—PIK3CG—ovarian cancer	4.21e-07	0.000163	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—PIK3CB—ovarian cancer	4.18e-07	0.000162	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—PIK3CD—ovarian cancer	3.7e-07	0.000143	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—PTEN—ovarian cancer	3.61e-07	0.00014	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—PIK3CB—ovarian cancer	3.23e-07	0.000125	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—PIK3CA—ovarian cancer	3.01e-07	0.000116	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—PIK3CA—ovarian cancer	2.98e-07	0.000115	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—PTEN—ovarian cancer	2.79e-07	0.000108	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—PIK3CA—ovarian cancer	2.55e-07	9.85e-05	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—AKT1—ovarian cancer	2.46e-07	9.5e-05	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—AKT1—ovarian cancer	2.44e-07	9.41e-05	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—AKT1—ovarian cancer	2.08e-07	8.05e-05	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.97e-07	7.6e-05	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—AKT1—ovarian cancer	1.61e-07	6.21e-05	CbGpPWpGaD
